Efficacy of Bilateral Modified Catheter Antegrade Cerebral Perfusion in Acute Type A Aortic Dissection Surgery

May 5, 2025 updated by: China Medical University Hospital

A Retrospective Cohort Study Evaluating the Efficacy of Bilateral Modified Catheter Antegrade Cerebral Perfusion (Modified bACP) in Acute Type A Aortic Dissection Surgery

This retrospective cohort study aims to evaluate the efficacy of a Bilateral Modified Catheter Antegrade Cerebral Perfusion (Modified bACP) technique in acute Type A aortic dissection surgery. Medical records from January 1, 2021, through October 31, 2024, at China Medical University Hospital will be reviewed. The primary outcomes include in-hospital mortality and stroke rate, while secondary outcomes include ICU/hospital stay, mechanical ventilation duration, and other postoperative complications (e.g., acute kidney injury, sepsis, myocardial infarction).

Study Overview

Detailed Description

Background and Rationale Acute Type A aortic dissection (ATAAD) is a life-threatening condition requiring urgent surgical repair. Prolonged circulatory arrest increases the risk of neurological complications. Bilateral antegrade cerebral perfusion (bACP) has shown potential to reduce ischemic injury. However, conventional bACP requires additional surgical access. This study examines a Modified bACP approach that may reduce surgical trauma while maintaining adequate cerebral perfusion.

Objectives This retrospective cohort study evaluates whether Modified bACP improves postoperative outcomes compared to conventional perfusion strategies in ATAAD surgery at China Medical University Hospital (2021/1/1-2024/10/31).

Methods We will collect and analyze medical records of adult patients who underwent ATAAD repair, comparing those who received Modified bACP to those managed with conventional perfusion.

Outcome Measures

Primary Outcomes:

In-hospital mortality 30-day mortality

Secondary Outcomes:

Hospital length of stay (day) ICU length of stay (day) Mechanical ventilation duration (hours) Need for tracheostomy Stroke Postoperative neurological deficit Paraplegia Coma Atrial fibrillation (Af) Myocardial infarction Acute kidney injury (AKI) Dialysis requirement Reoperation for bleeding Sepsis Significance This study aims to provide comprehensive data on the safety and efficacy of Modified bACP in ATAAD surgery, potentially improving neurological protection and reducing other major complications and resource utilization. The findings may guide clinical practice and inform future protocol developments.

Study Type

Observational

Enrollment (Actual)

273

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taichung City, Taiwan, 40447
        • China Medical University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients diagnosed with acute Type A aortic dissection who underwent surgical repair at China Medical University Hospital. The population includes individuals receiving either Modified bACP or conventional perfusion during the specified period.

Description

Inclusion Criteria:

  • Adults (≥ 18 years old) who underwent acute Type A aortic dissection repair at China Medical University Hospital between January 1, 2021, and October 31, 2024.

Exclusion Criteria:

  • Preexisting severe neurological impairment (e.g., stroke or other major neurological deficits before surgery).
  • Age < 18 years.
  • Pregnant patients.
  • Insufficient or missing medical records preventing data analysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Modified bACP Group
Patients who underwent acute Type A aortic dissection repair using the Bilateral Modified Catheter Antegrade Cerebral Perfusion (Modified bACP) technique. This observational group received the modified perfusion strategy aimed at reducing surgical trauma and enhancing cerebral protection.
A modified bilateral catheter antegrade cerebral perfusion technique used for acute Type A aortic dissection repair. This approach aims to reduce surgical trauma by avoiding additional right axillary access while maintaining stable cerebral perfusion.
Conventional Perfusion Group
Patients who underwent acute Type A aortic dissection repair using the conventional brain perfusion technique (e.g., standard bilateral antegrade cerebral perfusion). This group serves as the comparison cohort for evaluating the effects of the modified technique.
Patients receiving the conventional perfusion strategy for aortic arch surgery, which may include standard bilateral ACP based on the surgeon's preference and the patient's condition.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stroke
Time Frame: Through hospital discharge (on average about 14 days post-surgery)
New-onset cerebrovascular accident or imaging-confirmed stroke during hospitalization.
Through hospital discharge (on average about 14 days post-surgery)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Neurological Deficit
Time Frame: Through hospital discharge (on average about 14 days post-surgery)
Any persistent neurological deficit (e.g., motor/sensory deficits) identified after surgery.
Through hospital discharge (on average about 14 days post-surgery)
30-day Mortality
Time Frame: Assessed at 30 days post-surgery
All-cause mortality occurring within 30 days after the surgical procedure.
Assessed at 30 days post-surgery
Hospital Stay (day)
Time Frame: From end of surgery to hospital discharge (up to 21 days).
Total number of days from the operation date to the date of hospital discharge.
From end of surgery to hospital discharge (up to 21 days).
ICU Stay (day)
Time Frame: From end of surgery to ICU discharge (up to 10 days).
Length of stay in the intensive care unit after surgery.
From end of surgery to ICU discharge (up to 10 days).
Mechanical Ventilation (hour)
Time Frame: From end of surgery until extubation (up to 72 hours).
Duration of mechanical ventilation in hours.
From end of surgery until extubation (up to 72 hours).
Acute Kidney Injury (AKI)
Time Frame: During the index hospitalization (on average about 10-14 days post-surgery)
Acute kidney injury defined by changes in serum creatinine or urine output (e.g., KDIGO criteria).
During the index hospitalization (on average about 10-14 days post-surgery)
Dialysis Requirement
Time Frame: During the index hospitalization (on average about 10-14 days post-surgery)
Proportion of patients requiring renal replacement therapy (dialysis) postoperatively.
During the index hospitalization (on average about 10-14 days post-surgery)
Reoperation for Bleeding
Time Frame: During the index hospitalization (on average about 72 hours post-surgery)
Number of patients requiring a return to the operating room for bleeding control or hematoma.
During the index hospitalization (on average about 72 hours post-surgery)
Sepsis
Time Frame: During the index hospitalization (on average within 7 days post-surgery)
Incidence of sepsis as defined by current guidelines (e.g., Sepsis-3), typically requiring positive cultures and organ dysfunction.
During the index hospitalization (on average within 7 days post-surgery)
Atrial Fibrillation (Af)
Time Frame: During the index hospitalization (on average within 7 days post-surgery)
New-onset atrial fibrillation or documented arrhythmia episodes requiring clinical management.
During the index hospitalization (on average within 7 days post-surgery)
Myocardial Infarction
Time Frame: During the index hospitalization (on average about 10-14 days post-surgery)
Clinically confirmed myocardial infarction based on ECG changes, cardiac enzymes, and clinical symptoms.
During the index hospitalization (on average about 10-14 days post-surgery)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: En-Bo Wu, M.D., Department of Anesthesiology, China Medical University Hospital, China Medical University, Taichung City 404, Taiwan

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Actual)

October 31, 2024

Study Completion (Actual)

April 11, 2025

Study Registration Dates

First Submitted

April 16, 2025

First Submitted That Met QC Criteria

April 22, 2025

First Posted (Actual)

April 24, 2025

Study Record Updates

Last Update Posted (Actual)

May 7, 2025

Last Update Submitted That Met QC Criteria

May 5, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • CMUH113-REC1-183 (Other Identifier: Institutional Review Board, China Medical University Hospital)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD will not be shared due to institutional privacy policies and IRB regulations that restrict the release of patient-level data. The de-identified data are only approved for internal use by the research team and cannot be disclosed to external parties without additional ethics approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Type A Aortic Dissection

Clinical Trials on Modified Catheter Antegrade Cerebral Perfusion (Modified bACP)

Subscribe